Recently, ERK3 has also been shown to phosphorylate AKT, promoting anchorage-independent survival in several types of cancer, including TNBC, through a mechanism associated with its role in increasing tumour burden in in vivo models (16). This evidence concerns the gene MAPK6 and cancer.